CG Oncology eyes PIVOT-006 readout with $985m in cash
CG Oncology has reported its third-quarter 2026 financials and outlined a dense near-term clinical calendar, with Phase 3 topline data from the PIVOT-006 trial expected this month and two further 12-month datasets due in December.
The Dallas-based company held $984.5 million in cash, cash equivalents and marketable securities as of 30 September 2026, down modestly from $1.0 billion at the end of the second quarter. Management said the balance is sufficient to fund operations through 2029, giving the company an unusually long cash runway for a late-stage oncology biotech that has yet to bring a product to market.
Three trials, one drug
Cretostimogene grenadenorepvec is an intravesically delivered oncolytic immunotherapy being evaluated across two Phase 3 trials and a multi-cohort study in non-muscle invasive bladder cancer (NMIBC). PIVOT-006 is testing the agent as adjuvant monotherapy in patients with intermediate-risk and high-grade Ta tumours of no more than 3 cm, an indication the company describes as the first randomised registrational trial in that specific population. The trial's topline results are due before the end of November.
In December, CG Oncology expects to report 12-month efficacy and safety data from two additional cohorts: BOND-003 Cohort P, which focuses on BCG-unresponsive papillary-only disease, and CORE-008 Cohort CX, covering BCG-exposed high-risk and BCG-unresponsive patients. The company is also working to complete its biologics licence application to the FDA for cretostimogene in BCG-unresponsive NMIBC with carcinoma in situ, with submission targeted for the fourth quarter of 2026. The candidate carries both FDA Fast Track and Breakthrough Therapy designations for that indication.
Arthur Kuan, Chairman, President and Chief Executive Officer, described the period ahead as "eventful" and said the company remains confident in cretostimogene's potential to become "a backbone therapy for patients" across the NMIBC landscape.
Financial performance and commercial build-out
Research and development expenses rose to $39.2 million in the third quarter, up from $27.9 million in the same period a year earlier. The increase reflects higher clinical trial costs, chemistry, manufacturing and controls expenditure, and additional headcount. General and administrative expenses were broadly flat at $23.0 million, compared with $23.3 million a year ago. The net loss for the quarter was $56.9 million, or $0.64 per diluted share, against a net loss of $43.8 million, or $0.57 per share, in Q3 2025.
In October, CG Oncology strengthened its commercial team by appointing Isabel Kalofonos as Chief Commercial Officer. Kalofonos brings more than two decades of launch experience, including roles on paltusotine and mirvetuximab soravtansine, and her hire signals the company is building out its pre-launch infrastructure ahead of a potential BLA approval decision.
NMIBC is a competitive but evolving segment. The BCG-unresponsive population has historically had limited options beyond cystectomy, and several companies are pursuing intravesical and systemic approaches in the same setting. The scale of CG Oncology's clinical programme, spanning more than 700 patients across multiple cohorts, positions cretostimogene as one of the most extensively studied oncolytic candidates in bladder cancer. Whether the PIVOT-006 readout confirms the agent's earlier signals in a randomised setting will be closely watched by urologists, investors and potential commercial partners alike.